Associated Papers
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
41559357 (PubMed )
Supplement: 277_2026_6771_MOESM2_ESM.xlsx › TableS3
Clinical classification and molecular interpretation of germline pathogenic TP53 variations detected by multigene panel testing in patients with possible cancer predisposition.
Onder G et al.
Molecular Genetics and Genomics : Mgg, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
39774325 (PubMed )
Supplement: 41588_2024_2039_MOESM5_ESM.xlsx › SuppFig6
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
39140857 (PubMed )
Supplement: table_s1_bbae400.xlsx › Sheet1
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
36561320 (PubMed )
Supplement: Table2.xlsx › PIK3CA
Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma.
Leko V et al.
Journal for Immunotherapy of Cancer, 2021
34266885 (PubMed )
Supplement: jitc-2021-002882supp001.pdf
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.
Simbolo M et al.
Virchows Archiv : an International Journal of Pathology, 2018
30219970 (PubMed )
Supplement: 428_2018_2450_MOESM4_ESM.xlsx › Suppl_Table_4
Clinical Utility of Next-Generation Sequencing-Based Molecular Panel in Thyroid Nodules.
Gondaliya H et al.
Indian Journal of Endocrinology and Metabolism, 0
Select a paper to view details